# Afatinib Expanded Access Program

> **NCT01649284** · — · APPROVED_FOR_MARKETING · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** afatinib

## Key facts

- **NCT ID:** NCT01649284
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** 2012-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** — (—)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649284, "Afatinib Expanded Access Program". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01649284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*